Clinical trial
Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular…
NCT00071994 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00071994 |
|---|---|
| Title | Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) |
| Official title | A Phase II Study of ZD1839 (Iressa, Gefitinib, NSC 715055) in Advanced Unresectable Hepatocellular Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer |
| Intervention type | Drug, Other |
| Interventions | gefitinib, laboratory biomarker analysis |
| Enrollment | 59 |
| Start date | Feb 1, 2004 |
| Primary completion | May 1, 2005 |
| First posted | Nov 6, 2003 |
| Last update posted | Feb 27, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: